Business Description
Repare Therapeutics Inc
NAICS : 541714
SIC : 3741
ISIN : US7602731025
Share Class Description:
RPTX: Ordinary SharesTotal Employee Number:
129Description
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 329.25 | |||||
Equity-to-Asset | 0.91 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 0.1 | |||||
Beneish M-Score | -0.16 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 84.4 | |||||
3-Year EBITDA Growth Rate | 9.1 | |||||
3-Year EPS without NRI Growth Rate | 11.3 | |||||
3-Year FCF Growth Rate | 8 | |||||
3-Year Book Growth Rate | -19.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 37.07 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 86.4 | |||||
9-Day RSI | 77.35 | |||||
14-Day RSI | 73.23 | |||||
3-1 Month Momentum % | 43.58 | |||||
6-1 Month Momentum % | 62.66 | |||||
12-1 Month Momentum % | 123.48 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 10.71 | |||||
Quick Ratio | 10.71 | |||||
Cash Ratio | 9.69 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.5 | |||||
Shareholder Yield % | 1.45 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -667.31 | |||||
Net Margin % | -608.26 | |||||
EBITDA Margin % | -644.16 | |||||
FCF Margin % | -590.97 | |||||
OCF Margin % | -590.97 | |||||
ROE % | -53.35 | |||||
ROA % | -46.04 | |||||
ROIC % | -789.92 | |||||
3-Year ROIIC % | -63.92 | |||||
ROC (Joel Greenblatt) % | -2196.13 | |||||
ROCE % | -58.49 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 9.6 | |||||
PB Ratio | 0.99 | |||||
Price-to-Tangible-Book | 0.99 | |||||
EV-to-EBIT | -0.02 | |||||
EV-to-EBITDA | -0.03 | |||||
EV-to-Revenue | 0.17 | |||||
EV-to-Forward-Revenue | 0.02 | |||||
EV-to-FCF | -0.03 | |||||
Price-to-GF-Value | 2.82 | |||||
| Price-to-Net-Current-Asset-Value | 1.01 | |||||
| Price-to-Net-Cash | 1.13 | |||||
Earnings Yield (Greenblatt) % | -5000 | |||||
FCF Yield % | -61.41 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RPTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Repare Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 11.87 | ||
| EPS (TTM) ($) | -1.7 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | -0.09 | ||
| 3-Year Sortino Ratio | -0.11 | ||
| Volatility % | 49.59 | ||
| 14-Day RSI | 73.23 | ||
| 14-Day ATR ($) | 0.050011 | ||
| 20-Day SMA ($) | 2.58675 | ||
| 12-1 Month Momentum % | 123.48 | ||
| 52-Week Range ($) | 0.89 - 2.66 | ||
| Shares Outstanding (Mil) | 43.11 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Repare Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Repare Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 116 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 18 days | ||
| General meeting for 2026 | 2026-06-17 10:00 | 2.65 (+0.38%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 2.65 (+0.38%) | ||
| Annual report for 2025 | 2026-03-03 | 2.65 (+0.38%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-03 | 2.65 (+0.38%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 1.69 (-1.17%) | ||
| Second quarter earnings results for 2025 | 2025-08-08 | 1.52 (-1.30%) | ||
| General meeting for 2025 | 2025-06-17 10:00 | 1.45 (-0.68%) | ||
| First quarter earnings results for 2025 | 2025-05-13 | 1.36 (+0.00%) |
Show
Entries
Repare Therapeutics Inc Frequently Asked Questions
What is Repare Therapeutics Inc(RPTX)'s stock price today?
The current price of RPTX is $2.65. The 52 week high of RPTX is $2.66 and 52 week low is $0.89.
When is next earnings date of Repare Therapeutics Inc(RPTX)?
The next earnings date of Repare Therapeutics Inc(RPTX) is 2026-08-07 Est..
Does Repare Therapeutics Inc(RPTX) pay dividends? If so, how much?
Repare Therapeutics Inc(RPTX) does not pay dividend.
Guru Commentaries on NAS:RPTX
No articles.
Press Release
Articles on Repare Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers